Swedbank
CPRX

Swedbank’s Catalyst Pharmaceutical CPRX Stock Holding History

Swedbank’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.4M Buy
775,032
+158,900
+26% +$4.69M 0.02% 362
2026
Q1 		$15.3M Hold
616,132
– – 0.02% 428
2025
Q4 		$14.4M Hold
616,132
– – 0.01% 446
2025
Q3 		$12.1M Hold
616,132
– – 0.01% 461
2025
Q2 		$13.4M Hold
616,132
– – 0.02% 439
2025
Q1 		$14.9M Buy
+616,132
New +$13.9M 0.02% 405

Other funds holding CPRX

LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
OLA
Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Swedbank's CPRX Position: Q2 2026 in Review

Swedbank increased its Catalyst Pharmaceutical (CPRX) stake by 26% in Q2 2026, buying an estimated $4.69M and bringing the position to 775,032 shares worth $24.4M. The position accounts for 0.02% of the portfolio, ranked #362.

Swedbank first reported a position in CPRX in Q1 2025 and has held it in 6 quarters since. 36 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Swedbank held 775,032 shares of Catalyst Pharmaceutical worth $24.4M as of Q2 2026.
  • Swedbank bought 158,900 Catalyst Pharmaceutical shares in Q2 2026, an estimated $4.69M.
  • Catalyst Pharmaceutical made up 0.02% of Swedbank's portfolio in Q2 2026, its #362 holding.
  • Swedbank first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 6 quarters since.
  • 36 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Swedbank's 13F filing for Q2 2026, filed 15 Jul 2026.